Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has been issued a trademark registration for RECCE® from the Israeli Patent Office, Trademarks Department, in an effort to tap into the burgeoning Israeli pharmaceutical and biotech market.
This newly registered trademark further strengthens the company’s intellectual property portfolio with those already registered in the biggest pharmaceutical markets in the world such as Australia, USA, Europe, Japan, China and most recently in Hong Kong.
The Israeli pharmaceutical and biotech market has a well-established reputation for its world-class research facilities and high spending in research and development, broad international reach and a market value reaching US$5.3 billion in 2021.
Welcomed addition
Recce CEO James Graham said: “We are thrilled the receive this addition to Recce’s Intellectual Property portfolio.
This trademark is a welcomed advance in supporting the company’s Israeli opportunities over the time ahead.”
Trademark specifications
The international trademark registration no 1289603, formally assigns Israeli trademark no. 355216 for the RECCE® mark.
Classified under Class, specification of the trademark:
- antibiotics;
- antibiotics for human use; and
- pharmaceutical preparations, namely mixed antibiotic preparations.